Search

everythinglearnresearchcommunity

for

Search:↓

Newborns with the common rash Erythema Toxicum have many active mast cells in their skin, but these cells don't produce the LL-37 peptide.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

Simvastatin reduces inflammation and promotes hair regrowth in alopecia areata.

SOX11 and SOX4 help skin cells act like embryonic cells to heal wounds in mice.

New therapies are being developed that target integrin pathways to treat various diseases.

Female-pattern hair loss may involve an autoimmune-like process, suggesting new treatment options.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

Hair regrowth in alopecia universalis may be possible by altering immune cells.

Faulty Notch signalling may cause hair follicle changes and inflammation in hidradenitis suppurativa.

PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.

Hormones can improve wound healing by regulating the healing process.

ILC1-like cells can cause alopecia areata by themselves.

Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.

Angelica sinensis helps repair and regenerate the thymus in mice.

Too much IKZF1 and Ikaros protein may cause alopecia areata.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

Alopecia areata involves specific immune cells, offering potential treatment targets.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

The model helps understand and improve treatments for alopecia areata by simulating hair growth and immune cell interactions.

New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.

Folliculotropic Mycosis Fungoides requires stage-based treatment, with early stages using skin therapies and advanced stages needing aggressive treatments.

Stress can cause hair loss and trigger autoimmunity by damaging hair follicle cells.

Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

Immune activities and specific genes are important in male pattern baldness.

Alopecia areata may be treated by restoring hair follicle immune privilege and adjusting immune responses.

Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.